Business
Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Knee
Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRING...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Knee\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n EP-104IAR demonstrates trends to reduction in joint inflammation and improvement in cartilage quality and morphology compared to placebo\n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n Jan. 30, 2024\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced positive magnetic resonance imaging (\"MRI\") data from the Company's ongoing SPRINGBOARD Study, a Phase 2 randomized, double-blind, vehicle-controlled, parallel-group trial evaluating the safety and efficacy of EP-104IAR for the treatment of osteoarthritis (\"OA\") of the knee (NCT04120402).\n \n \n \"The positive results from the MRI sub-study of the SPRINGBOARD trial provide supportive clinical evidence that treatment with EP-104IAR does not appear to negatively impact cartilage health or exacerbate inflammatory conditions in the surrounding area, which is important information that supports continued clinical development of EP-104IAR,\" said Dr.\n \n James Helliwell\n \n , CEO of Eupraxia.\n \n \n The clinical data are based on the 12-month results from an MRI sub-study where subjects from the SPRINGBOARD study were invited to participate in an optional imaging analysis that was performed in parallel to data collection for the main study. MRI, including Dynamic Contrast Enhanced scans of the index knee and T2 Scans, were obtained as part of this sub-study. These MRI analyses included assessments of synovial inflammation (synovial thickness, synovial blood flow) and articular cartilage health (cartilage quality and morphology) for EP-104IAR versus placebo. Cartilage health, quality...